Previous Close | 0.3000 |
Open | 0.3000 |
Bid | 0.0000 |
Ask | 1.6000 |
Strike | 22.50 |
Expire Date | 2024-06-21 |
Day's Range | 0.3000 - 0.3100 |
Contract Range | N/A |
Volume | |
Open Interest | 55 |
Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today received from S&P Global, a leading rating agency, the change of its rating outlook to stable from negative (bbb-, stable outlook). Moody's changed the credit rating outlook from negative to stable on May 17 (baa3, stable outlook).
Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the presentation of nearly 40 company-affiliated research abstracts at the 61st European Renal Association (ERA) Congress, taking place May 23-26, 2024, in Stockholm, Sweden and virtually.
Fresenius Medical Care (FME), the global leader in providing products and services for people with kidney diseases, is executing its strategic turnaround plan and is well on track to achieve its goals for 2024.